When GLP-1 Coverage Changes, What Happens Next?

When GLP-1 Coverage Changes, What Happens Next?

For years, we asked members to take charge of their health. They did.

Members sought treatment. They explored new options. They acted on obesity, diabetes, and cardiometabolic risks that had gone unmanaged for years.

GLP-1 demand now exposes a benefits paradox. Employers encouraged action. Now many struggle to afford the response. Rising utilization has reduced the conversation to a false choice: absorb volatile pharmacy costs or restrict access.

Health plans and PBMs must help employer clients find a more durable answer to GLP-1 use.

Employers need more than coverage administration. They need a defensible strategy. Members need a coherent experience. Brokers need evidence that GLP-1 support can produce measurable value.

This pressure will shape ASO sales and renewals. Employers and advisors will ask how health plans, TPAs, and PBMs will govern costs, support members through coverage changes, and address clinical needs beyond medication.

A prescription is not a care model.

Access without coordinated clinical and behavioral support can produce erratic adherence, unmanaged side effects, fleeting behavior change, and no long-term plan.

Restricting access may curb immediate pharmacy exposure. It does not resolve obesity, cardiometabolic risk, or employee demand.

The coverage decision is only the beginning.

The real decision begins after coverage.

Coverage shows what options exist. It does not ensure members understand, get support, or improve.

Health plans and PBMs have pharmacy strategies, claims insights, care management, provider networks, engagement tools, and partners. Yet employers still struggle to see how these investments drive action and measurable health impact.

The challenge is not simply deciding whether to cover GLP-1s. It is connecting the pieces needed to make that coverage decision work.

Move beyond cover or cut.

Health plans and PBMs can offer employers better choices than absorbing costs or restricting access without addressing the root cause.

This requires coordination across pharmacy strategy, clinical support, member engagement, and behavior change.

The 2026 strategic guide shows where coordination often breaks and how health plans and PBMs can improve performance for employers.

The next GLP-1 decision should not be just about coverage. Make it about what supports that decision to work—and act on it now. Get the 2026 strategic guide now to make the next decision work.

Focus on what supports that decision and makes it work.

Get the GLP-1 strategy guide for health plans and PBMs now →

What health plans, TPAs, and PBMs need to know about changing GLP-1 coverage

Why are employers reconsidering GLP-1 coverage?

Employers are struggling to absorb and forecast rapidly rising utilization. Business Group on Health reports that employer coverage of GLP-1s for obesity fell from 72% in 2025 to 60% in 2026, reflecting broader pressure to contain volatile pharmacy costs. See the 2027 Employer Health Care Strategy Survey.

Is restricting GLP-1 coverage enough to control the underlying risk?

Restricting coverage may reduce immediate pharmacy exposure, but it does not eliminate obesity, cardiometabolic risk, or the need for sustained support. Peterson Health Technology Institute recommends clinically driven eligibility, behavioral and nutritional support, and structured pathways for members who taper or discontinue therapy. Review its employer GLP-1 coverage framework.

What role can health plans, TPAs, and PBMs play?

Health plans, TPAs, and PBMs can help ASO employer clients move beyond a binary choice between absorbing costs and restricting access. By connecting pharmacy strategy, clinical support, member engagement, and personalized communication, they can create a more coherent model around each coverage decision.

Move beyond the coverage decision

See where GLP-1 strategy breaks across the employer-client and member experience, and what health plans, TPAs, and PBMs must connect to improve adherence, strengthen outcomes, and protect employer and broker confidence.

Get the 2026 strategic guide →

Jennifer Musick, PharmD, vice president of clinical strategy at Navigate, will join BeneCard PBF at IFEBP’s 72nd Annual Employee Benefits Conference in New Orleans. Attend their Solutions Spotlight, LiveLife: A Coaching Program for Whole-Person Health, on Monday, October 26, from noon to 12:30 p.m.

Get the session details →